Pharma tech firms announce global MES partnership
Zenith Technologies and Werum IT Solutions to help improve pharma companies' production performance.
Zenith Technologies and Werum IT Solutions have formed a global partnership to support pharmaceutical companies with the implementation of manufacturing execution system (MES) technology to improve production performance.
The collaboration brings together Werum IT Solution’s MES PAS-X software, which is designed to increase efficiency, improve productivity and meet regulatory requirements during pharmaceutical manufacturing, with Zenith Technologies’ ability to integrate systems and provide on-the-ground automation technical support. The PAS-X software is used by the majority of the world’s top 30 pharmaceutical and biotech companies but also by many regional and mid-sized manufacturers.
The partnership, which was signed at Werum’s headquarters in Lüneburg, Germany, makes Zenith Technologies an Endorsed Service Partner of Werum IT Solutions in both the US and Europe. Zenith Technologies will support Werum customers during all MES implementation phases, delivering comprehensive support and consultancy services that complement Werum’s manufacturing IT solutions.
“We are delighted to partner with Zenith Technologies,” says Torsten Isenberg, Senior Director Services at Werum IT Solutions GmbH. “As an Endorsed Service Partner, Zenith Technologies has the knowledge and experience required to be part of our PAS-X service partner program. Our main objective is to ensure a high level of support for our customers through reliable, experienced and certified partners.”
Brendan O’ Regan, chairman and founder, Zenith Technologies, adds: “Given our combined expertise in automation and the similarities in our customer base, the collaboration represents a strategic move for both companies. By combining Werum’s MES technology with our technical implementation experience, we can provide customers with a high quality of service, training and local level support, helping them to remain both compliant and competitive. We are continually investing in training and working together with Werum and other solution providers to ensure we stay ahead with the latest technology.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.